New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies-Reference-Cited by-同舟云学术

New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies

Published:2021 Issue:48 Volume:11 Page:30315-30328
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Alanazi Mohammed M.¹,Elkady Hazem²^ORCID,Alsaif Nawaf A.¹,Obaidullah Ahmad J.¹^ORCID,Alkahtani Hamad M.¹^ORCID,Alanazi Manal M.¹,Alharbi Madhawi A.¹,Eissa Ibrahim H.²^ORCID,Dahab Mohammed A.²^ORCID

Affiliation:

1. Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11541, Saudi Arabia

2. Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt

Abstract

A new series of 3-methylquinoxaline-based derivatives having the same pharmacophoric features of VEGFR-2 inhibitors have been synthesized and evaluated for their antiproliferative activities against MCF-7 and HepG-2 cells.

Funder

King Saud University

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/RA/D1RA05925D

Reference88 articles.

1. The cell cycle and cancer

2. The cell cycle and cancer

3. Tyrosine kinase receptors as attractive targets of cancer therapy